A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
Links shared publicly online about this topic
NEJM -- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
content.nejm.org — “Original Article from The New England Journal of Medicine -- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease” View full resource at content.nejm.org
Most Recently Shared on June 8, 2009 at 12:03 pm By:
Best treatment for heart disease AND diabetes? No clear cut answer: http://bit.ly/qJYfQ
NEJM -- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
content.nejm.org — “Original Article from The New England Journal of Medicine -- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease” View full resource at content.nejm.org
Most Recently Shared on June 7, 2009 at 10:32 pm By:
RT @THEHCC BARI 2D supports COURAGE. Stenting no better than medical tx, even for T2 diabetes. More pain for stent cos. http://bit.ly/mIVhL
Endocrinology Article | Coronary Artery Disease
mdlinx.com — “Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results” View full resource at mdlinx.com
Most Recently Shared on November 18, 2010 at 1:29 pm By:
Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabet... http://bit.ly/cB5JHV #diabetes
Endocrinology Article | Coronary Artery Disease
mdlinx.com — “Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results” View full resource at mdlinx.com
Most Recently Shared on November 18, 2010 at 12:45 pm By:
Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes a... http://bit.ly/crdm6x #endo
Internal Medicine Article | Diabetes Mellitus, Type 2
mdlinx.com — “A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial” View full resource at mdlinx.com
Most Recently Shared on January 21, 2011 at 11:30 am By:
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes m... http://bit.ly/dRGmp2 #medicine
Family Medicine Article | Diabetes Mellitus, Type 2
mdlinx.com — “A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial” View full resource at mdlinx.com
Most Recently Shared on January 24, 2011 at 7:36 am By:
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabete... http://bit.ly/es09D5 #FamPractice
BARI 2D cost-effectiveness
theheart.org — “New data from the BARI 2D trial comparing medical therapy vs revascularization in diabetics shows higher up-front costs of revascularization are only partially offset by long-term savings.” View full resource at theheart.org
Most Recently Shared on November 18, 2009 at 9:00 pm By:
BARI 2D cost-effectiveness analysis favors medication over PCI for less severe CVD in diabetic patients http://bit.ly/4lNRnW #SS09 #aha09
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Ohio Family Practice
We are the premier family medicine practice in Akron and Western Summit County. Drs. Dom Dera, Sabin, & Cajigas are accepting new patients.
-
Scott Hensley
Writer and editor for Shots, NPR's health blog.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement

